Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors

This phase I study was designed to: (1) determine the maximum tolerated dose (MTD) and recommended dose (RD) of the fibroblast growth factor receptor (FGFR) inhibitor futibatinib in Japanese patients with advanced solid tumors, and (2) examine the antitumor activity of the RD in patients with gastri...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Shitara, Kohei, Kojima, Takashi, Kuboki, Yasutoshi, Matsubara, Nobuaki, Bando, Hideaki, Yoh, Kiyotaka, Naito, Yoichi, Hirai, Hiroshi, Kurokawa, Yukinori, Kato, Terufumi, Morizane, Chigusa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899610/
https://www.ncbi.nlm.nih.gov/pubmed/35838190
http://dx.doi.org/10.1111/cas.15486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899610/
https://www.ncbi.nlm.nih.gov/pubmed/35838190
http://dx.doi.org/10.1111/cas.15486

Ejemplares similares